Cyprotex

𝗖𝘆𝗽𝗿𝗼𝘁𝗲𝘅 𝗮𝗻𝗱 Evotec 𝘄𝗶𝗹𝗹 𝗮𝘁𝘁𝗲𝗻𝗱 𝘁𝗵𝗲 𝗗𝗠𝗗𝗚 𝟱𝟭𝘀𝘁 𝗔𝗻𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗿𝘆 𝗢𝗽𝗲𝗻 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝘁𝗵𝗶𝘀 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿. Dermot McGinnity, EVP Head of Global Discovery DMPK, will be amongst the speakers in the 2025 DMDG Debate session, which will address the following motion: "This house believes that social media has more potential to positively impact drug discovery and development than peer reviewed articles". • 𝗖𝗮𝗺𝗯𝗿𝗶𝗱𝗴𝗲, 𝗨𝗞 • 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝟵: 𝗧𝗵𝗲 𝗗𝗠𝗗𝗚 𝗗𝗲𝗯𝗮𝘁𝗲 • 𝗪𝗲𝗱𝗻𝗲𝘀𝗱𝗮𝘆 𝟯𝗿𝗱 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿, 𝟭𝟳:𝟯𝟬 𝗕𝗦𝗧 Arrange meetings with our colleagues, Steve Madden, SVP, Head, Global Operations Cyprotex and Rachel Upcott Gill, Principal Scientist, Drug Metabolism: https://hubs.ly/Q03zfCF00

Missed our latest newsletter? No problem! Catch up on all the latest news and developments from Cyprotex, your ADME-Tox specialist, available here on LinkedIn. Connect with us to discuss how we can support your projects: enquiries@cyprotex.com

Greetings from #JSOT in Okinawa! If you're on site, our colleagues, Tim Potter, Robert Brown, PhD and Masaaki Yatsu will be happy to discuss your projects and how we can support your safety and toxicology needs. Find them at Booth #48. #DrugDiscovery #Toxicology

Even the most sophisticated AI/ML models are only as good as the data behind them. That’s why at Cyprotex, we deliver high-quality, standardized ADME-Tox datasets essential for training robust machine learning models. Our scalable, high-throughput platforms ensure data precision, reproducibility and rapid turnaround, helping AI-driven teams turn virtual predictions into real-world breakthroughs. With decades of expertise, automated high-throughput platforms and a commitment to data integrity, we empower AI drug discovery companies to generate scalable, reproducible datasets optimized for their machine learning model development. Download our latest service sheet to learn more: https://hubs.ly/Q03v8MzB0 Interested in partnering with us? Get in touch to discuss your project at enquiries@cyprotex.com #ai #drugdiscovery #cyprotex #theadmetoxspecialists

Hi All, I am presenting on Thursday July 3rd at the JSOT meeting in Okinawa: Please come along and say hello!! Date:  July 3 (Thu), 2025 Time: 16:30-18:00pm Location: Okinawa Convention Center, Japan In this presentation, I will discuss the latest advances in New Approach Methodologies (NAMs) and Transcriptomics with integrated AI to de-risk organ toxicity in drug discovery projects. Also if you wish please schedule a meeting with myself or our team to explore how we can support your research needs. Visit our event page for full details: https://lnkd.in/ex_NqVCJ Hopefully see you there!!

Cyprotex is excited to be exhibiting at RICT 2025 – the 59th International Conference on Medicinal Chemistry in Orléans, France, from July 2–4! We’re looking forward to engaging with the scientific community and exploring the latest trends shaping the future of medicinal chemistry. Whether you're interested in comprehensive drug discovery and development solutions or expert ADME-Tox support, our team is here to help accelerate your research. If you're attending, reach out to schedule a meeting: https://hubs.ly/Q03twGvN0. We’d love to connect! #RICT2025 #Cyprotex #MedChem #theadmetoxspecialists

We’re excited to attend the 52nd Annual Meeting of the Japanese Society of Toxicology (JSOT 2025) from 2–4 July in beautiful Okinawa, Japan. Join our expert Dr. Paul Walker as he presents: “Leveraging an Integrated AI and New Approach Methodologies (NAMs) Safety Strategy to Understand Multi-Organ Safety Risk in Drug Discovery.” Our Business Development colleagues, Tim Potter and Robert Brown, will be available at the booth throughout the conference. Stop by to learn more about how our ADME-Tox and NAMs capabilities could help you to make faster data-driven decisions in drug discovery and development. If you'd like to arrange a meeting with our scientific experts, feel free to drop us a request here: https://hubs.ly/Q03tj8VM0 #JSOT2025 #Cyprotex #NAMs #ADMETox #theadmetoxspecialists #Toxicology

That’s a wrap on NYSCC Suppliers’ Day in New York! It was fantastic to see the energy and innovation on display throughout this exciting two-day event, and we are proud to have had Cyprotex in the mix. Ralf Geiben Lynn, AVP Business Development at Cyprotex, is on-site meeting partners and exchanging ideas. If you didn’t get a chance to connect during the show, or you're still in New York and would like to chat, we’d love to meet up! Otherwise, feel free to reach out to us at enquiries@cyprotex.com to discuss your project. #theadmetoxspecialists #cyprotex #cosmetics

While statins are a cornerstone in cardiovascular care, side effects such as statin-associated myopathy remain a concern – especially among the aging population, who often require polypharmacy. But what happens when statin-related transporters are inhibited by a co-medication? Read more in our latest blog: https://hubs.ly/Q03n4TYv0 At Cyprotex, we use our transporter science expertise to assess how your investigational drug may affect statin exposure and therefore DDI risk. Get in touch to discuss your project at enquiries@cyprotex.com #theadmetoxspecialists #cyprotex #transporters

𝗔𝗔𝗖𝗥 𝟮𝟬𝟮𝟱 𝗺𝗮𝘆 𝗯𝗲 𝗼𝘃𝗲𝗿, 𝗯𝘂𝘁 𝘁𝗵𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲! Evotec’s team was proud to present groundbreaking scientific posters showcasing our latest advancements in oncology research. From innovative drug discovery approaches to cutting-edge translational models, our work is driving the future of cancer therapeutics. If you missed us at the event, you can still explore our findings! 𝗖𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝗼𝘂𝗿 #𝗔𝗔𝗖𝗥𝟮𝟱 𝗽𝗼𝘀𝘁𝗲𝗿𝘀 𝗲𝗻𝘁𝗶𝘁𝗹𝗲𝗱, Mice humanized for the immune system as validated tool for therapeutic antibody development, and our second poster, A Novel CD2-Targeted Costimulatory Bispecific Antibody Platform for Enhancing CD3 T Cell Engager-Based Cancer Immunotherapy here- https://hubs.ly/Q03lNwKd0 𝗔 𝗵𝘂𝗴𝗲 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝘁𝗼 𝗲𝘃𝗲𝗿𝘆𝗼𝗻𝗲 who visited our presentations, engaged in discussions, and continues to push the boundaries of oncology innovation with us. Let’s keep the conversation going! What were your key takeaways from AACR? #OncologyResearch #CancerTherapeutics